Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04317105 |
| Title | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | Yes |
| Sponsors | National Cancer Institute (NCI) |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | CAN |
CKB BOOST